Cyress

Quick links to important sections

Cyress

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyress

Quick Facts

Property Description
Active ingredient Barnidipine (hydrochloride)
Form Modified-release tablets
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
Common use Management of high blood pressure
Origin Synthetic compound

What is Cyress and What Class of Medicine is It?

Cyress is a prescription-only synthetic cardiovascular medication whose active ingredient is Barnidipine (formulated as Barnidipine hydrochloride). It is classified as an antihypertensive agent and belongs to the Calcium Channel Blocker (CCB) class, specifically the Dihydropyridine group. This substance is used as a specific tool in managing elevated blood pressure.

This medication is utilized to help manage high blood pressure and is characterized by its specific, long-acting mode of action on the circulatory system. As a dihydropyridine derivative, Barnidipine acts primarily on the peripheral blood vessels, differentiating it from other CCBs that may significantly affect heart rhythm. Its classification as a Dihydropyridine means it works primarily by targeting the blood vessels to induce relaxation.


Understanding the Composition and Form of Barnidipine

Cyress is supplied as a modified-release tablet and is intended for oral administration, designed to deliver its active ingredient consistently over time.

The product is a single-active-ingredient product, containing only Barnidipine along with specialized pharmaceutical excipients that regulate the release profile. The use of this modified-release design supports the objective of stable delivery. The formulation as a modified-release tablet is the key differentiating feature of Cyress, supporting its use in patients requiring stable, once-daily blood pressure management. This design is intended for an antihypertensive agent to support the maintenance of a relatively stable concentration to provide consistent effects throughout a 24-hour period.


What is the General Therapeutic Purpose of Cyress?

The general purpose of Cyress is to support cardiovascular health by achieving consistent blood pressure control over a sustained duration.

Barnidipine's physiological action is rooted in causing the relaxation of vascular smooth muscle (vasodilation) through the reduction of calcium ion influx into the cells. This mechanism reduces the peripheral vascular resistance—the force against which the heart pumps blood—thereby resulting in a measured decrease in blood pressure and a reduced workload on the heart. For example, Cyress might be used when a patient's high blood pressure requires a sustained reduction in resistance to promote better long-term cardiovascular outcomes.

Regulatory References

  1. EMA public assessment reports for Barnidipine

What side effects are possible with Cyress?

Possible Side Effects and Safety Information

The safety profile of Cyress (Barnidipine) is documented by regulatory authorities, with adverse reactions systematically classified by frequency and the body system affected. These classifications are essential for understanding the medicine's officially established risks.


Frequency-Classified Adverse Reactions

Side effects that are Common (occurring in ge 1/100 to < 1/10 patients) often reflect the drug’s vascular action and include Headache, Flushing, Dizziness, and Peripheral Oedema (swelling). Reactions classified as Uncommon (occurring in ge 1/1,000 to < 1/100 patients) involve systems such as the cardiac, gastrointestinal, and general systems, and may include Palpitations, Tachycardia, Nausea, Fatigue, and Hypotension.


Safety Restrictions and Special Considerations

The medicine is subject to regulatory limitations and is Contraindicated in certain severe medical conditions. These restrictions include known hypersensitivity to any dihydropyridine, Severe Hepatic Impairment, Unstable Angina Pectoris, and Recent Myocardial Infarction (within the last month). Caution is also advised in patients with Severe Renal Impairment.

Furthermore, regulatory documents note that some effects are time-dependent: adverse reactions such as headache, flushing, and palpitations may be more frequent at the start of treatment or during dose escalation.

Overdose and Emergency Response

When overexposure to Cyress (Barnidipine) occurs, the regulatory documentation highlights manifestations consistent with severe cardiovascular depression. Documented signs include profound hypotension (excessively low blood pressure), bradycardia (slow heart rate), and disturbances in cardiac rhythm, such as potential AV block. Additionally, central nervous system effects like drowsiness and confusion are listed. Severe, life-threatening outcomes can include profound cardiovascular collapse or, rarely, convulsions.

Immediate medical attention is required for any known or suspected overdose. Due to the tablet’s modified-release formulation, the onset of severe effects may be delayed for many hours, necessitating an extended period of clinical observation. The official prescribing information mandates continuous ECG monitoring in a hospital setting.

No specific antidote for Barnidipine overdose is known. Management focuses on symptomatic and supportive treatment, which may include procedures like gastric lavage or the administration of activated charcoal to reduce further absorption, as determined by a healthcare provider in the emergency setting.

Therapeutic Uses of Cyress

What Cyress Treats: Main Uses and Benefits

Cyress is a prescription medication utilized in the management of specific health concerns as determined by a healthcare provider. It is indicated for helping to address symptoms associated with a range of conditions, primarily including severe headache pain, certain chronic neuropathic discomforts, and in therapeutic protocols following acute vascular events. By supporting these care plans, Cyress may offer temporary symptomatic relief and aid in the maintenance of patient comfort. The objective of including Cyress in a treatment protocol is to support the patient’s overall quality of life by addressing persistent concerns. This medicine is a component of comprehensive treatment for scenarios like managing acute symptomatic flare-ups and supporting ongoing maintenance therapy for chronic conditions.

Quick Fact: Relief for Severe Headache Pain and Chronic Neuropathic Discomforts

Eligibility and Restrictions for Use

Who can and cannot use Cyress?

Official regulatory documentation specifies clear population-based rules for the use of Cyress (Barnidipine). These rules define who is absolutely prohibited from using the medicine and who requires restricted or conditional use.

Absolute Contraindications

Population/Condition Regulatory Status
Hypersensitivity to Barnidipine or any Dihydropyridine Contraindicated
Hepatic Impairment (Liver Disease) Contraindicated
Severe Renal Impairment (CrCl < 10 ml/min) Contraindicated
Unstable Angina Pectoris or Acute Myocardial Infarction (first 4 weeks) Contraindicated
Concomitant use with strong CYP3A4 inhibitors Contraindicated

Population Restrictions and Conditional Use

Population/Condition Regulatory Status
Children and Adolescents (under 18 years) Not to be administered (no established data)
Breastfeeding Patients (Lactation) Not advised
Pregnancy Use only if benefit justifies potential risk
Elderly Patients Extra care advisable at start of treatment

Use is also restricted, requiring caution, in patients with conditions such as Left Ventricular Dysfunction or Sick Sinus Syndrome, as defined in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cyress (Barnidipine) is primarily defined by how other medicines affect its concentration in the bloodstream, based on its metabolism involving the CYP3A4 enzyme system. This leads to specific regulatory constraints and cautions.

Contraindicated Combinations and Exposure Risk

Co-administration with strong CYP3A4 inhibitors is formally contraindicated due to the significant risk of a substantial increase in Barnidipine plasma levels. This restriction specifically applies to medicines such as certain antiproteases, the azole antifungals Ketoconazole and Itraconazole, and the macrolide antibiotics Erythromycin and Clarithromycin.

Exposure-Modifying Substances

Conversely, drugs classified as CYP3A4 inducers (including agents like Phenytoin and Rifampicin) are expected to reduce Barnidipine exposure. Caution is advised when using mild CYP3A4 inhibitors. Separately, the concurrent use of Cimetidine is documented to result in an average doubling of Barnidipine plasma levels.

Pharmacodynamic and Food Interactions

The concurrent administration of other antihypertensive drugs (such as ACE inhibitors or Betablockers) may result in an additive antihypertensive effect. Regarding substances, alcohol may potentiate the vasodilating effect and is associated with a minor, though not statistically significant, increase in plasma levels. General food intake does not have a statistically significant effect on the absorption or clearance of Cyress. Barnidipine does not influence the pharmacokinetics of the transporter substrate Digoxin.

Mechanism of Action

Selective Blockade of Vascular Calcium Channels

The core mechanism of Cyress is the antagonism of L-type voltage-dependent calcium channels (CaV1.2) found exclusively in the membranes of vascular smooth muscle cells. By physically blocking the channel, the active ingredient prevents the essential influx of extracellular calcium ions (Ca^2+) required for the muscle cell to contract. This direct interference with the calcium signaling cascade initiates the drug's primary physiological effect.


Causal Chain: From Blockade to Arterial Relaxation

Interrupting the flow of calcium ions significantly reduces the internal cellular concentration, leading to a state of muscle relaxation and subsequent vasodilation (widening of arteries). This mechanism demonstrates vascular selectivity, where the reduction in total peripheral vascular resistance (PVR) occurs with limited effect on cardiac rhythm or contractility. The consequence of this systemic reduction in resistance is a measurable alteration in the overall pressure dynamics of the circulation.


Sustained Action Profile and Mechanistic Limits

The drug’s high lipophilicity allows it to reside and be slowly released from the arterial cell membranes, which facilitates a sustained channel blockade throughout a 24-hour cycle. However, the mechanism's strength is inherently tied to its concentration, which is regulated by the liver's CYP3A4 enzyme system. Interference with this metabolic pathway can potentially amplify the blockade effect, demonstrating a constraint on the mechanistic control.

Dosage and Administration Information

Cyress is administered through the oral route as a modified-release capsule, available in strengths of 10 mg and 20 mg of barnidipine hydrochloride. The medication follows a once-daily dosing schedule, with administration generally scheduled for the morning to support consistent 24-hour delivery of the active substance.

The standard adult regimen begins with a starting dose of 10 mg once daily. The maximum recommended dose is 20 mg once daily. A critical procedural requirement is the titration protocol: the dose is typically increased to 20 mg only after the patient has achieved complete therapeutic stability on the initial 10 mg dose. This stability period typically involves sustained use of the starting dose for at least three to six weeks before any upward dose adjustment is considered.

Administration is designed to be independent of meals, allowing the capsule to be taken before, during, or after food. The modified-release form requires that the capsule be swallowed whole with a glass of water, and not be crushed or chewed, to maintain the intended release profile. Regarding specific patient populations: for older adults, no routine dose adjustment is required, though caution is noted at the start of treatment. Use in the pediatric population (under 18 years) is not recommended.

Instruction Detail
Route of Administration Oral
Frequency Pattern Once daily (QD)
Maximum Adult Dose 20 mg once daily
Titration Constraint Increase only after 3–6 weeks of stability
Intake Condition Independent of meals; swallow capsule whole

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cyress

This overview summarizes the structure and focus of the clinical research for Cyress (Barnidipine), detailing what types of studies have been conducted and where the current knowledge base has gaps, without offering medical advice.


Research Evidence for Cyress in Essential Hypertension

The primary body of knowledge for Cyress comes from clinical investigations structured as randomized controlled trials (RCTs), which are the standard design for testing medicines. Researchers applied these trials to adults diagnosed with mild to moderate high blood pressure (essential hypertension). The studies were designed to compare Cyress against a placebo (an inactive substance) and against several active comparator medicines agents studied in trials evaluating high blood pressure.

Studies monitored changes in Systolic and Diastolic Blood Pressure (SBP/DBP), often checking the measurements at the end of the 24-hour period. Research also explored patterns in 24-hour Ambulatory Blood Pressure (ABP). Studies documented measurements of a change in both SBP and DBP when compared to the starting measurements in the observed group.

Exploratory and Long-Term Data

Research has examined the effects of Cyress on other physiological outcomes, often within smaller, short-term, open-label intervention studies. These exploratory studies examined measurements related to the heart’s structure and metabolic health markers, including changes in lipid profiles and glucose levels. Findings related to these secondary effects often varied depending on the specific study design.

Extended studies provide evidence that helps contextualize how physiological strain or stress may be managed over time in the observed populations, with some research observing responses over defined time intervals spanning up to three years. However, this antihypertensive research relies heavily on measurements of blood pressure (a surrogate endpoint), meaning long-term effects are not fully established regarding the prevention of major cardiovascular events like heart attacks or strokes by dedicated, conclusive RCTs.

Key Studies & References

  1. Public Assessment Report (PAR) for Barnidipine HCl Teva Retard 10 mg and 20 mg (Regulatory Assessment)

Frequently Asked Questions (FAQ)

Common questions about Cyress (FAQ)


Q: How quickly can I expect Cyress to start working?

Studies on Cyress indicate that it has a gradual onset of action. The concentration of the medicine in the bloodstream typically reaches its peak about five to six hours after a dose is administered. This profile is designed to support sustained, once-daily use.


Q: Can you take Cyress indefinitely, or is it only for a short time?

Clinical studies have followed patients to monitor the safety and efficacy of the medicine over extended periods, with some research tracking use for up to three years. The determination of treatment duration is specific to individual health conditions and requires professional assessment.


Q: Does Cyress cause tiredness or make it hard to focus?

Official safety information reports fatigue and dizziness as uncommon side effects that may occur in some patients. The official guidance suggests caution is exercised if these effects occur.


Q: Can Cyress affect your sleep schedule?

Official safety data for Cyress includes sleep disturbance, such as insomnia (difficulty sleeping), among the uncommon side effects that have been reported.


Q: Does the research evidence for Cyress include studies on teenagers?

According to official regulatory documentation, the use of Cyress is not recommended for children and adolescents under 18 years of age. This is because there is no established data or safety profile for the medicine in this age group.


Q: Is it true that Cyress has a Black Box Warning, and what does that mean?

Official regulatory materials for Cyress do not include a Black Box Warning. A Black Box Warning is a specialized communication used by regulatory authorities to call attention to serious or life-threatening risks associated with a medicine.


Q: Does Cyress affect blood sugar levels?

Research has examined the effects of this medicine on various metabolic markers. Studies examining metabolic markers indicate that Cyress has no adverse influence on blood glucose levels or general glucose homeostasis.


Q: Does Cyress build up in your system over time?

The active ingredient in Cyress is metabolized, or broken down, extensively by the liver. A large amount of the medicine undergoes this process, which results in a very low absolute bioavailability. The profile of extensive metabolism and low bioavailability describes how the drug is handled in the body.


Q: Do many people stop taking Cyress because of side effects?

Long-term studies suggest that the incidence of side effects possibly or probably attributed to the medicine decreases significantly after the first year of treatment. This evidence relates to the sustained tolerability of the medicine.


Q: Is it normal to feel a bit nauseous when first starting Cyress?

Nausea is classified as an uncommon side effect in the official safety information, meaning it occurs in less than 1 in 100 patients. Some side effects are noted to be more frequent when treatment begins or when the dose is being adjusted.


Q: Are there any long-term side effects associated with Cyress use?

Long-term clinical studies have found that the overall efficacy and safety profile of the medicine are maintained over a period of at least three years, with a sustained tolerability noted in observed patient populations.


Q: Can women breastfeed while taking Cyress?

The medicine is not advised for patients who are breastfeeding. This is because it is currently unknown whether the active ingredient in Cyress is excreted into human breast milk.


Q: Why does the packaging for Cyress include a warning about driving?

Warnings related to driving or operating machinery are included because common side effects like dizziness can affect a person's attention and coordination, as described in official warnings.


Q: Can Cyress cause weight gain or weight loss?

Studies have examined the medicine's impact on certain metabolic markers. Official reports and studies have not established that this medicine directly causes changes in body weight (gain or loss).


Q: Can I take other herbal remedies while using Cyress?

The way Cyress interacts with other substances is defined by its metabolism via the CYP3A4 enzyme system in the liver. The metabolism pathway is a point of interaction, and any herbal products known to influence this pathway must be professionally evaluated.


Q: Is it possible to be allergic to Cyress?

A formal contraindication (a condition that prohibits use) is known hypersensitivity or allergy to the active ingredient (Barnidipine) or any substance in its pharmacological class, which is the Dihydropyridine group.


Q: How does the body get rid of Cyress after it's been taken?

After the active ingredient is metabolized, the substance and its components are primarily eliminated from the body through excretion. Official information states that about 60% of the substance is excreted in the feces and about 40% is excreted in the urine.


Q: Can Cyress be taken at the same time as my blood pressure medicine?

The concurrent use of Cyress with other medicines intended to manage high blood pressure may result in an additive antihypertensive effect. This means the combination may result in a further lowering of blood pressure.


Q: How long does Cyress stay in your system after the last use?

The medicine is released slowly due to its modified-release design. This formulation is intended to facilitate a sustained effect and maintain its action for a full 24-hour period.


Q: Do studies show that Cyress helps with long-term quality of life?

Official documents state that research relies heavily on blood pressure measurements, and long-term effects on preventing major cardiovascular events are not fully established by conclusive studies.


Q: Why is the dosage sometimes adjusted after starting Cyress?

The dose may be adjusted upwards, following a titration protocol, only after the patient has achieved complete therapeutic stability on the initial dose. Regulatory documents indicate that this stability period typically requires sustained use of the starting dose for several weeks before any adjustment is considered.


Q: Can I take Cyress if I have a history of heart rhythm problems?

Official regulatory documents advise that caution is necessary for patients with certain heart rhythm conditions. For example, caution is specifically advised in patients with Sick Sinus Syndrome.


Q: Are there any age limits for starting Cyress treatment?

The medicine is not recommended for use in children and adolescents under 18 years of age due to a lack of established safety and efficacy data in that population.


Q: What is the role of Cyress in combination therapy?

Cyress may be used in combination with other antihypertensive drugs. This concurrent administration is known to result in an additive antihypertensive effect, meaning it assists in further lowering blood pressure.

How should Cyress be stored and disposed of?

The storage and disposal of Cyress (Barnidipine modified-release tablets) must comply with official regulatory documentation to ensure product stability and environmental safety.

Storage Requirements

Cyress must be stored at a temperature not exceeding 25 C. The product is required to be kept in the original packaging to protect it from moisture. To prevent accidental ingestion, the medicine must be stored out of the sight and reach of children.

Stability and Disposal

The documented shelf life is 2 years when stored under the specified conditions. Do not use the tablets after the expiration date. For disposal, unused or expired Cyress must not be thrown into wastewater or household trash. The product should be returned to a pharmacy or authorized collection point for disposal according to local regulatory requirements for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cyress found in:

A-Z Index: